18 September 2025
Roche to Acquire 89bio and Its Phase 3 FGF21 Analog for MASH Treatment
Roche enhances its CVRM portfolio with 89bio's pegozafermin, targeting MASH. The deal is valued up to $3.5 billion, with potential milestone payments. Completion expected Q4 2025.
